कृपया अन्य खोज का प्रयास करें
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Martin Brygger Moller | - | 2021 | Independent Chairman of the Board |
Jorgen Vilhelm Lovenorn Bardenfleth | 67 | 2018 | Independent Vice-Chairman of the Board |
Palle Christophersen | 65 | - | Member of Scientific Advisory Board |
Susan E. Bates | - | - | Member of Scientific Advisory Board |
Richard L. Schilsky | 72 | 2021 | Member of Clinical Advisory Board |
Martine Jannigje van Vugt | - | 2022 | Independent Director |
Thomas T. W. Seufferlein | - | 2021 | Member of Clinical Advisory Board |
Eric Van Cutsem | - | 2021 | Member of Clinical Advisory Board |
Josep Tabernero | - | 2021 | Member of Clinical Advisory Board |
Keld Flintholm Jorgensen | 52 | 2022 | Independent Director |
Alejandra Maria Cristina Bonifacini Mork | 62 | 2022 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है